



US 20250262168A1

(19) **United States**

(12) **Patent Application Publication**
Maguire et al.

(10) **Pub. No.: US 2025/0262168 A1**

(43) **Pub. Date: Aug. 21, 2025**

(54) **COMBINATION THERAPEUTIC REGIMENS
WITH
1,6-DIBROMO-1,6-DIDEOXY-DULCITOL**

Publication Classification

(51) **Int. Cl.**

A61K 31/047 (2006.01)

A61K 31/196 (2006.01)

A61K 31/4045 (2006.01)

A61K 31/4184 (2006.01)

A61K 31/495 (2006.01)

A61K 31/506 (2006.01)

A61K 31/69 (2006.01)

A61P 35/00 (2006.01)

(52) **U.S. Cl.**

CPC *A61K 31/047* (2013.01); *A61K 31/196*

(2013.01); *A61K 31/4045* (2013.01); *A61K*

31/4184 (2013.01); *A61K 31/495* (2013.01);

A61K 31/506 (2013.01); *A61K 31/69*

(2013.01); *A61P 35/00* (2018.01)

(71) Applicant: **Eleison Pharmaceuticals LLC,**
Princeton, NJ (US)

(72) Inventors: **Patrick Maguire,** Foster City, CA
(US); **Robert Johnston,** Princeton, NJ
(US); **Seth Lederman,** New York, NY
(US)

(73) Assignee: **Eleison Pharmaceuticals LLC,**
Princeton, NJ (US)

(21) Appl. No.: **19/066,610**

(22) Filed: **Feb. 28, 2025**

Related U.S. Application Data

(63) Continuation of application No. 17/606,026, filed on
Oct. 23, 2021, filed as application No. PCT/US2020/
029350 on Apr. 22, 2020, now abandoned.


(60) Provisional application No. 62/837,761, filed on Apr.
24, 2019.

(57)

ABSTRACT

Methods of treating a subject suffering from a brain tumor are described herein wherein said methods comprise administering a therapeutically effective amount of a crystalline polymorph of 1,6-dibromo-1,6-dideoxy-dulcitol (DBD) including combination therapies with synergistic second cancer treatments. Also disclosed are methods of screening subjects sensitive to a crystalline DBD polymorph and treating those subjects demonstrating sensitivity.

CTG IC50 Dibromodulcitol: T98 cells



CTG= CellTite-Glow, viability assay

NT= Non-Treated control cell culture

IC50= Half maximal inhibitory conc.

■ day 5 □ day 8

Figure 1





Figure 2



COMBINATION THERAPEUTIC REGIMENS WITH 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a Continuation Application of U.S. Ser. No. 17/606,026, filed Oct. 23, 2021, which is a § 371 National Stage Application of PCT/US20/29350 filed on Apr. 22, 2020, which claims priority to US 62/837,761 filed on Apr. 24, 2019, which are all hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

[0002] Methods of treating cancer by administering 1,6-dibromo-1,6-dideoxy-dulcitol (dibromodulcitol or DBD), including crystalline DBD polymorphs, in combination with specific anti-cancer moieties is shown to have enhanced safety and efficacy.

INTRODUCTION

[0003] Cancer is the second leading cause of death in the United States, exceeded only by heart disease. Despite recent advances in cancer diagnosis and treatment, surgery and radiotherapy may be curative if a cancer is found early, but current drug therapies for metastatic disease are mostly palliative and seldom offer a long-term cure. Even with new chemotherapies entering the market, the need continues for new drugs effective in monotherapy or in combination with existing agents as first line therapy, and as second and third line therapies in treatment of resistant tumors.


[0004] One example of a potential chemotherapeutic used to treat cancer is 1,6-dibromo-1,6-dideoxy-dulcitol (dibromo dulcitol or DBD). The crystal structure of DBD was first published by Simon and Sasvari in *Acta. Cryst.* (1971) B27, 806-815. Kellner et al., reported that DBD had a selective a vigorous antitumor effect. Kellner et al., "1,6-Dibromo-1,6-Dideoxy-Dulcitol: A New Antitumoral Agent," *Nature* (1967) 28; 213 (5074):402-3. However, in these studies, DBD was prepared by treating dulcitol with aqueous hydrobromic acid saturated with gaseous hydrogen bromide at temperatures less than 00C. This process is no longer considered a safe method of making DBD. Moreover, it was reported in the literature that DBD was poorly soluble.

[0005] The present invention addresses the continued need to improve and develop new cancer treatments that have better safety and efficacy profiles.

SUMMARY OF THE INVENTION

[0006] This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject.

[0007] Described herein is the use of 1,6-dibromo-1,6-dideoxy-dulcitol, including crystalline DBD polymorphs, in combination with specific anti-cancer moieties to treat cancer. DBD has the molecular weight of 307.98 g/mol, the molecular formula C₆H₁₂Br₂O₄, and the following structure:



[0008] Specifically, preferred embodiments include a method of treating a subject suffering from cancer tumor, wherein said method comprises administering a therapeutically effective amount of a crystalline polymorph of 1,6-dibromo-1,6-dideoxy-dulcitol (DBD). Examples of such cancer that can be treated as described herein include, but are not limited to adenocarcinoma, sarcoma, skin cancer, melanoma, bladder cancer, brain cancer, breast cancer, uterine cancer, ovarian cancer, prostate cancer, or lung cancer.

[0009] In preferred embodiments, the brain cancer is selected from an astrocytoma, meningioma, oligodendroglioma, mixed glioma and ependymoma. In further preferred embodiments, the brain tumor is a glioblastoma multiforme.

[0010] In further preferred embodiments, the subject is a human.

[0011] In even further preferred embodiments, the method further comprises administering a second cancer treatment selected from Temozolomide, radiation, ABT-888, Bortezomib, Imatinib, Panobinostat or BIBR-1532. In such embodiments, the DBD crystalline polymorph works synergistically with the second cancer treatment. In further embodiments, the method of claim 6, wherein the radiation therapy is delivered by a radiation-delivering system, including a gantry-based system, a robotic radiosurgery system, a subcutaneous implant, or a radioisotope.

[0012] In other preferred embodiments, the method further comprises: (A) obtaining or having obtained glioma cells from the subject; (b) testing or having tested the glioma cells in vitro for sensitivity to the DBD crystalline polymorph; and (c) administering the DBD crystalline polymorph to the subject who has demonstrated sensitivity in step (b). Performing this method may identify agents in combination with the DBD crystalline polymorph that have improved activity and enhanced efficacy at potentially lower doses leading to improved safety and fewer side effects.

DESCRIPTION OF THE DRAWINGS

[0013] Embodiments are illustrated by way of example (and not limitation) in the figures of the accompanying drawings, in which like references, indicate similar elements and in which:

[0014] FIG. 1: Histogram from T98 cell cultures demonstrating the percentages of living cells at five and eight days following crystalline DBD polymorph treatment, compared to the non-treated cells considered 100% viability.

[0015] FIG. 2: Histogram from U373 cell cultures demonstrating the percentages of living cells at five and eight days following crystalline DBD polymorph treatment, compared to the non-treated cells considered 100% viability.

DETAILED DESCRIPTION OF THE INVENTION

[0016] While certain embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations,

changes, and substitutions will occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments described herein are, in some circumstances, employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

[0017] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in the application including, without limitation, patents, patent applications, articles, books, manuals, and treatises are hereby expressly incorporated by reference in their entirety for any purpose.

DEFINITIONS

[0018] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art, such as in the arts of peptide chemistry, cell culture, chemistry and biochemistry. Standard techniques are used for molecular biology, genetic and biochemical methods (see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3rd ed., 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel et al., *Short Protocols in Molecular Biology* (1999) 4th ed., John Wiley & Sons, Inc.), which are incorporated herein by reference.

[0019] As used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural nouns unless the content clearly dictates otherwise. For example, reference to “a chemotherapeutic” includes a mixture of two or more such chemotherapeutics or a plurality of such chemotherapeutics.

[0020] As used herein, the term “comprise” or variations thereof such as “comprises” or “comprising” are to be read to indicate the inclusion of any recited integer (e.g. a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g. features, element, characteristics, properties, method/process steps or limitations) but not the exclusion of any other integer or group of integers. Thus, as used herein, the term “comprising” is inclusive and does not exclude additional, unrecited integers or method/process steps.

[0021] In embodiments of any of the compositions and methods provided herein, “comprising” may be replaced with “consisting essentially of” or “consisting of”. The phrase “consisting essentially of” is used herein to require the specified integer(s) or steps as well as those which do not materially affect the character or function of the claimed invention. As used herein, the term “consisting” is used to indicate the presence of the recited integer (e.g. a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g. features, element, characteristics, properties, method/process steps or limitations) alone.

[0022] As used herein, “DBD” refers to 1,6-dibromo-1,6-dideoxy-dulcitol having the crystal structure as reported in the literature in *Acta. Cryst.* (1971) B27, 806-815.

[0023] The terms “crystalline DBD polymorph” or “crystalline polymorph” or “crystalline polymorphic form of DBD” refers to a crystalline form of 1,6-Dibromo-1,6-dideoxy-dulcitol as described in WO2016/205299 and US 2018/0362427, herein incorporated by reference in its entirety.

[0024] The term “subject”, as used herein in reference to individuals suffering from cancer and encompasses mammals and non-mammals. In a preferred embodiment, the subject is a human.

[0025] The terms “effective amount”, “therapeutically effective amount” or “pharmaceutically effective amount” as used herein, refer to an amount of at least one agent or compound being administered that is sufficient to treat cancer. The result is the reduction and/or alleviation of the signs, symptoms, or causes of such disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in a disease. An appropriate “effective” amount in any individual case is determined using techniques such as a dose escalation study. Additionally, “effective amount”, “therapeutically effective amount” or “pharmaceutically effective amount” means that compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject (e.g. human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.

[0026] In the present invention, a “tumor” or “cancer” is defined as a population of heterogeneous cells, collectively forming a mass of tissue in a subject resulting from the abnormal proliferation of malignant cancer cells. Thus, a “tumor” will contain both normal or “non-cancerous” cells and “cancer” or “cancerous” cells.

[0027] As used herein, “and/or” is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example, “A and/or B” is to be taken as specific disclosure of each (i) A, (ii) B and (iii) A and B, just as if each is set out individually.

[0028] As used herein, the term “about” is used to refer to an amount that is approximately, nearly, almost, or in the vicinity of being equal to or is equal to a stated amount, e.g., the state amount plus/minus about 5%, about 4%, about 3%, about 2% or about 1%.

[0029] It is to be understood that the application discloses all combinations of any of the above aspects and embodiments described above with each other, unless the context demands otherwise. Similarly, the application discloses all combinations of the preferred and/or optional features either singly or together with any of the other aspects, unless the context demands otherwise.

EXAMPLES

[0030] The invention will now be further illustrated with reference to the following examples. It will be appreciated that what follows is by way of example only and that modifications to detail may be made while still falling within the scope of the invention.

[0031] In the following Examples, the following abbreviations are used:

DEFINITIONS AND ABBREVIATIONS	
A2.5	ABT-888 concentration 2.5 μM
A10	ABT-888 concentration 10 μM
B1	Bortezomib concentration 1 nM

-continued

DEFINITIONS AND ABBREVIATIONS	
B2.5	Bortezomib concentration 2.5 nM
B5	BIBR1532 concentration 5 μM
B10	BIBR1532 concentration 10 μM
CTG	CellTiter-Glo (viability assay)
DBD	Dibromodulcitol
DMSO	Dimethyl SulfOxide (solvent for drugs, used as control)
GBM	Glioblastoma Multiforme
GBM(rec)	Recurrent Glioblastoma Multiforme
GSC's	Glioma serum-free Stem-like Cell cultures
IC50	half maximal inhibitory concentration
I4	Imatinib concentration 4 μM
I15	Imatinib concentration 15 μM
MGMT	O6-methylguanine-methyltransferase
NT	Non-Treated control cell culture
P5	Panobinostat concentration 5 nM
P20	Panobinostat concentration 20 nM
RLU	Relative Luminescence Units
RTX	radiotherapy
TMZ	Temozolomide
T50	TMZ concentration 50 μM
T100	TMZ concentration 100 μM
½IC50	half the concentration of the IC50
3 Gy	three gray radiation
6 Gy	six gray radiation

Overview

[0032] The crystalline DBD polymorph was studied in an in vitro system using two human glioma cell lines with an attempt to identify DBD's ability to decrease cell viability, and to identify synergy with other compounds. The following studies Examples 1-3 were performed. The following results are presented:

- [0033] a. Demonstration of a suitable in vitro concentration range of the polymorphic DBD drug that can be used for other cell studies (Example 1);
- [0034] b. Determination of IC 50 (half maximal inhibitory concentration) values on day 5, and day 8, over twenty patient derived cell free cultures (Example 2); and
- [0035] c. Determination if the effect of the DBD (½ of the IC 50 dose and IC 50 dose) is enhanced in combination with TMX (temozolomide), radiation therapy, or other targeted therapies in a panel of twenty primary serum-free cell cultures (Example 3).

Example 1: Determination of the Suitable Concentration Range of Crystalline DBD Polymorph DBD Using Two Glioma Cell Lines

[0036] Since the concentration range of crystalline DBD polymorph to demonstrate effect in patient-derived serum-free glioma cell cultures is not yet known, a large range of concentrations was tested on two glioma cell lines. These

lines were seeded in triplicate in a 96-wells plate, in a dilution of 500 cells/well. The ATP-based Cell Titer-Glo® (CTG) assays were performed at 5 and 8 days, to monitor cell growth and efficiency of DBD to effect decreased cell viability. FIGS. 1 and 2 show the histogram results of the two used glioma cell lines, T98 and U373.

[0037] Specifically, the histograms are normalized in percentages, where the non-treated cells have a 100% survival. The two lowest concentrations, 0.1 μM and 0.3 μM, were not effective. Moreover, almost all cells treated with 300 μM DBD dose are not viable. However, a concentration range between 1 and 100 μM was selected and was next tested on twenty patient-derived serum-free cell cultures.

Example 2: Determination of the IC50 Values of Crystalline DBD Polymorph DBD in a Panel of Twenty Patient Derived Primary Serum-Free Cell Cultures

[0038] To assess the effects of crystalline DBD polymorph on the growth of patient derived GSC's (Glioma serum-free Stem-cell like cultures), dose-response assays were performed on twenty cultures.

[0039] For determining the IC50 of crystalline DBD polymorph, concentrations from 1 μM to 100 μM were applied. A dose-dependent decrease in viability was found, and the IC50 values of could be calculated using linear regression analysis. An overview of all IC50 values (μM) of DBD on the twenty cell cultures from both day 5 and day 8 analysis is shown in Table 1. Specifically, looking at Table 1, a high variation of different IC50 values is seen in this panel of patient derived GSC's. In addition, no correlation is seen between the MGMT promotor methylation status and the amount of the IC50 value. (MGMT methylation status can be a prognostic, and in some studies, has significantly improved the survival rate in patients with unresectable glioblastoma multiforme, who received concomitant radiation therapy and Temozolomide).

[0040] However, over time, between five and eight days, cells get more sensitive to the drug and lower IC50 values are observed. See, for example GS102peri, wherein IC50 at 5 days is 41.77 while the IC50 at 8 days has decreased to 11.94. This is surprising as known mechanisms of decreased responsiveness of a tumor cell to a particular chemotherapeutic include (1) decreased uptake of agents into or increased export out of the cell; (2) increased inactivation of agents in the cell; (3) enhanced repair of the DNA damage produced by the alkylating agents; and (4) the absence of cellular mechanisms that produce cytotoxicity in response to DNA damage. Thus, to observe an increase in sensitivity to cell killing of a cancer cell to treatment of a DBD polymorph in combination of one of the described chemotherapeutics is surprising.

TABLE 1

Table 1: An overview of the measured IC50 values of DBD in μM for all twenty primary serum-free cell cultures.				
GS#	Passage	MGMT promotor methylation status	IC50 5 d	IC50 8 d
GS102peri	18	(core) Methylated (tumor & cells)	41.77	11.94
GS104peri	22	(core) Methylated (tumor & cells)	3.48	0.57
GS184	15	Methylated (tumor & cells)	18.6	1.96
GS186core	14	Unmethylated Methylated (tumor & cells)	4.56	1.94
GS186peri	14	(core) Unmethylated Methylated (tumor &	4.24	2.28

TABLE 1-continued

Table 1: An overview of the measured IC50 values of DBD in μ M for all twenty primary serum-free cell cultures.				
GS#	Passage	MGMT promotor methylation status	IC50 5 d	IC50 8 d
		cells)		
GS203	20	Methylated (tumor & cells)	28.68	10.53
GS224	17	Methylated (tumor & cells)	33.28	10.87
GS245	13	Unmethylated (tumor & cells)	6.58	3.35
GS249	18	Methylated (tumor)	0.63	0.24
GS257	13	Unmethylated (tumor & cells)	11.86	10.22
GS261	11	Methylated (tumor)	3.44	1.85
GS279core (1)	13	Methylated (tumor & cells)	3.6	—
GS279core (2)	16	(core) Methylated (tumor & cells)	7.64	—
GS279peri	13	Unmethylated (tumor & cells)	31.49	8.33
GS281	13	Unmethylated (tumor & cells)	10.56	5.55
GS289	13	Methylated (tumor) & Unmethylated (cells)	6.88	3.22
GS304	14	(core) Methylated (tumor & cells)	105.62	12.19
GS323peri	17	Methylated (cells)	4.75	—
GS324core	16	Methylated (tumor & cells)	8.96	2.98
GS359	14	Unmethylated (tumor & cells)	11.84	7.27
GS365	14	MGMT promotor methylation status	14.63	5.69

Core means cells obtained from the tumor core.

Peri means cells from the invading margin, or *periphery* of the patient's tumor.

Example 2: Determination of Whether the Effect of the DBD Polymorph ($\frac{1}{2}$ of IC50 Dose and IC50 Dose) is Enhanced in Combination With TMZ (Temozolomide, a Chemotherapeutic Alkylating Agent, Used for Treatment Against Gliomas), RTX (Radiation Therapy) or any Other Compound, in a Panel of Twenty Primary Serum-Free Cell Cultures

[0041] Crystalline DBD polymorph treatment was combined with chemotherapy, radiotherapy and targeted inhibitors to determine whether the crystalline DBD polymorph form could: enhance efficacy of the conventional therapies; enhance efficacy when combined with newer *targeted* therapies; or would make (a subset of) cultures more sensitive to this treatment.

[0042] Therefore, cultures were treated with:

[0043] a. Crystalline DBD polymorph at IC50 and at $\frac{1}{2}$ IC50 doses (determined at day 5); and

[0044] b. Two different concentrations of either Temozolomide, radiotherapy, ABT-888 (PARP (Poly ADP-ribose polymerase) inhibitor), Bortezomib (proteasome inhibitor), Imatinib (Bcr-Abl, PDGF and c-KIT recep-

tor tyrosine kinase inhibitor), Panobinostat (pan-HDAC (histone deacetylase inhibitor) or BIBR1532 (telomerase inhibitor).

[0045] Tables 2 (Day 5) and 3 (Day 8) show the enhancement factors (viability percentage of most effective monotherapy divided by viability percentage, in combination with temozolomide or radiation therapy) for all used twenty cell cultures for all treatment combinations. In some cases, effects of crystalline DBD polymorph treatment (decreased cell viability) were seen compared to monotherapy Temozolomide, radiation, ABT-888, Bortezomib, Imatinib, Panobinostat or BIBR1532.

[0046] The *heat map* (heat map=representation of data in the form of a table in which data values are represented as different colors) with *darker grey colors* represents larger integer values within the cells of the table, making an easier visualization of the data. The *darker* the data cell, the more effective the combination of both therapies compared to the most effective monotherapy. As is shown in Tables 2 and 3, both Imatinib and Panobinostat overall, have the highest enhancement factors.

Table 2

Day 5	TMZ	RTX	ABT-888	Bortezomib	Imatinib	Panobinostat	BIBR1532
GS102periNS (p20+p21)	1.268	1.115	1.248	1.481	1.512	1.591	1.414
GS104periNS (p21+p22)	1.101	1.063	1.175	0.984	1.912	1.339	-
GS184NS (p18+p19)	1.362	0.953	1.084	0.542	3.072	1.712	1.752
GS186coreNS (p18)	1.751	1.376	1.394	-	2.166	2.557	1.787
GS186periNS (p15)	2.167	0.920	1.134	-	2.903	2.105	2.900
GS203NS (P19+p18)	1.055	1.270	-	-	1.676	-	-
GS224NS (p17)	1.335	1.183	1.105	0.954	1.778	4.399	0.969
GS245NS (p16+p15)	1.099	1.386	1.256	1.043	1.681	1.129	1.364
GS249NS (p17)	1.602	1.437	2.994	1.013	2.918	1.074	0.909
GS257NS (p16+p17)	1.005	1.115	0.922	0.970	2.938	1.643	1.322

Day 5	TMZ	RTX	ABT-888	Bortezomib	Imatinib	Panobinostat	BIBR1532
GS261NS (p13)	1.271	1.270	1.388	1.567	5.953	1.392	-
GS279coreNS (p12+p13)	1.440	1.702	1.321	2.252	6.790	5.962	1.526
GS279periNS (p16+p15)	1.162	0.939	1.146	1.265	1.673	1.943	1.361
GS281NS (p15)	1.264	0.690	0.933	0.826	-	1.480	0.641
GS289NS (p15+p16)	1.376	1.700	1.112	0.870	1.336	2.519	1.383
GS304NS (p16)	1.147	1.665	1.245	2.208	-	4.406	-
GS323periNS (p20+p19)	1.553	1.728	1.106	1.060	5.330	1.656	0.959
GS324coreNS (p19)	1.700	1.057	1.275	0.962	1.979	3.192	1.282
GS359NS (p15+p14)	1.830	1.532	1.175	1.940	2.123	4.343	2.499
GS365NS (p17+p16)	1.156	0.996	1.096	0.919	6.982	2.914	1.767

Table 2: An overview of the enhancement factors of the most effective monotherapy, and most effective corresponding combination therapy for all twenty primary serum-free cell cultures of day 5 measurement data.

Table 3

Day 8	TMZ	RTX	ABT-888	Bortezomib	Imatinib	Panobinostat	BIBR1532
GS102periNS (p20+p21)	1.309	1.082	1.055	1.518	1.881	3.863	2.661

Day 8	TMZ	RTX	ABT-888	Bortezomib	Imatinib	Panobinostat	BIBR1532
GS104periNS (p21+p22)	0.987	0.969	1.810	1.374	3,820	1.796	1.247
GS184NS (p18+p19)	1.531	0.849	1.044	0.639	-	2.357	1.367
GS186coreNS (p18)	2.029	2.185	1.359	-	8,644	5.363	1.498
GS186periNS (p15)	1.220	1.208	1.319	2.614	19,154	8.116	1.010
GS203NS (P19+p18)	1.159	1.616	-	-	2,042	1.651	1.110
GS224NS (p17)	1.470	0.978	1.201	1.011	4,423	7.387	0.469
GS245NS (p16+p15)	1.088	1.228	0.991	1.043	2,149	1.202	1.936
GS249NS (p17)	-	2.357	5.030	0.952	-	0.944	-
GS257NS (p16+p17)	0.858	1.103	1.053	0.978	5,243	1.590	2.162
GS261NS (p13)	1.462	1.209	1.631	1.676	10,658	2.253	-
GS279coreNS (p12+p13)	-	-	-	-	-	-	-
GS279periNS (p16+p15)	1.129	1.075	1.102	0.961	4,138	5.488	1.214
GS281NS (p15)	1.161	0.691	0.812	0.892	-	4.353	2.457
GS289NS (p15+p16)	1.032	1.271	1.113	1.664	1,285	3.535	1.879
GS304NS (p16)	1.134	2.435	1.933	8.179	-	5.405	1.065
GS323periNS (p20+p19)	-	-	-	-	-	-	-
GS324coreNS (p19)	1.377	1.045	1.322	1.028	-	9.253	1.713
GS359NS (p15+p14)	1.700	1.238	1.148	2.420	6.002	5.512	1.168

Day 8	TMZ	RTX	ABT-888	Bortezomib	Imatinib	Pandobinostat	BIBR1532
GS365NS (p17+p16)	1.019	0.566	1.052	0.939	12.015	3.253	2.954

Table 3: An overview of the enhancement factors of the most effective monotherapy and most effective corresponding combination therapy for all twenty primary serum-free cell cultures of the day 5 measurement data.

Summary and Conclusions

[0047] Chemical moieties, including therapeutic agents, may be synthesized to yield different crystalline structures. In many cases, these differing 'polymorphs', by virtue of their crystalline structure, can also have differing physico-chemical properties.

[0048] With changes in physicochemical properties, the polymorph can also have differing therapeutic profiles, that can alter safety and efficacy of the delivered compound when used therapeutically in humans. This may affect the polymorphs use with other adjuvant or combination drugs and therapies. This is especially important with combination therapies for oncology conditions.

[0049] The methods and results presented have identified a therapeutic in vitro dose range in patient derived glioma cell cultures, and have demonstrated that these effects are not influenced by MGMT status when treated with the crystalline DBD polymorph as described in WO2016/205299 and US 2018/0362427.

[0050] Moreover, with regard to other combination therapies, treatment with the DBD polymorph enhanced the cytotoxic effect when combined with another alkylating agent, temozolomide (by 50%) and with radiation treatment (by 30%).

[0051] When combined with newer targeted therapies (described below), the combination of the DBD polymorph and the newer targeted therapies has shown an enhanced effectiveness in in vitro patient derived cell studies. Specifically, a selection of targeted drugs was tested in combination with DBD in the panel of 20 patient derived cell cultures. This selection covered the most important pathways in the initiation of and continued growth of the malignancy human glioblastoma, such as:

- [0052]** a. bcr/abl, c-kit and pdgfr Tyrosine kinase
- [0053]** b. HDAC
- [0054]** c. Telomerase inhibition
- [0055]** d. Proteasome inhibition
- [0056]** e. DNA repair (PARP) inhibition

[0057] From these results (high enhancement factor, most cases) were achieved with HDAC inhibition (Panobinostat) and inhibition of Ras/MapK pathway, Src/Pax/Fak/Rac pathway, PI3K/AKT/BCL-2 pathway and JAK/STAT pathway combined (downstream effects of Bcr-Abl pathway), using the tyrosine kinase inhibitor, Imatinib.

[0058] Example 3-Incorporation of Disclosure WO2016/205299 (U.S. Pat. No. 20,180,362327)

[0059] As described in paragraphs [007-010] in WO2016/205299 (U.S. Pat. No. 20,180,362327), the DBD polymorph has a molecular weight of 307.98 g/mol and the molecular formula $C_6H_{12}Br_2O_6$.

[0060] In one aspect described herein are crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol characterized by peaks at 19.59° (100.00) and 24.380° (79.52) and 31.260° (8.32) and 34.500° (25.56) and 34.810° (22.83) and 39.260° (23.63) at $2\theta \pm 0.1^\circ$. In further embodiments, such a crystalline polymorph is further characterized by at least two peaks selected from 19.59° (100.00) and 24.380° (79.52) and 31.260° (8.32) and 34.500° (25.56) and 34.810° (22.83) and 39.260° (23.63) at $2\theta \pm 0.1^\circ$. In further embodiments, such a crystalline polymorph is further characterized by at least three peaks selected from 19.59° (100.00) and 24.380° (79.52) and 31.260° (8.32) and 34.500° (25.56) and 34.810° (22.83) and 39.260° (23.63) at $2\theta \pm 0.1^\circ$. In further embodiments, such a crystalline polymorph is further characterized

by at least four peaks selected from 19.59° (100.00) and 24.380° (79.52) and 31.260° (8.32) and 34.500° (25.56) and 34.810° (22.83) and 39.260° (23.63) at $2\theta \pm 0.1^\circ$. In further embodiments, such a crystalline polymorph is further characterized by at least five peaks selected from 19.59° (100.00) and 24.380° (79.52) and 31.260° (8.32) and 34.500° (25.56) and 34.810° (22.83) and 39.260° (23.63) at $2\theta \pm 0.1^\circ$.

[0061] In yet further embodiments, the crystalline polymorph exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in FIG. 1 in WO2016/205299 (U.S. Pat. No. 20,180,362327). In further embodiments, the crystalline polymorph exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in FIG. 2 in WO2016/205299 (U.S. Pat. No. 20,180,362327). In yet further embodiments, the crystalline polymorph exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern described in Table 1 in WO2016/205299 (U.S. Pat. No. 20,180,362327). In yet further embodiments, the crystalline polymorph exhibits a beta angle of 96° as compared to the literature reported beta angle of 98° .

[0062] In a related aspect described herein are crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol, characterized by an endothermic point onset at about 184.4° C. and peak at approximately 191° C. as determined by differential scanning calorimetry. In a further embodiment, the crystalline polymorph is characterized by a differential scanning calorimetry pattern substantially the same as the differential scanning calorimetry pattern shown in FIG. 3 and/or FIG. 4 in WO2016/205299 (U.S. Pat. No. 20,180,362327).

REFERENCES

- [0063]** 1. Chang, A. Y., et al., *Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study* (E1181). *Am J Clin Oncol*, 1998. 21 (1): p. 99-104.
 - [0064]** 2. Csetenyi, J., et al., *The distribution of [3H]-dibromodulcitol in the central nervous system of patients with brain tumour*. *Eur J Cancer Clin Oncol*, 1983. 19(10): p. 1389-92.
 - [0065]** 3. Berghauer Pont, L. M., et al., *The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells*. *Genes Cancer*, 2014. 5(11-12): p. 445-59.
 - [0066]** 4. Lee, J., et al., *Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines*. *Cancer Cell*, 2006. 9(5): p. 391-403.
 - [0067]** 5. Fael Al-Mayhany, T. M., et al., *An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours*. *J Neurosci Methods*, 2009. 176(2): p. 192-9.
 - [0068]** 6. Nikanjam, M., S. Liu, and R. Kurzrock, *Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013*. *Int J Cancer*, 2016. 139 (9): p. 2135-41.
1. A method of treating a subject suffering from cancer, wherein said method comprises administering a therapeuti-

cally effective amount of a crystalline polymorph of 1,6-dibromo-1,6-dideoxy-dulcitol (DBD) and a cancer treatment selected from Temozolomide, radiation, ABT-888, Bortezomib, Imatinib, Panobinostat or BIBR-1532 wherein the DBD polymorph works synergistically with the cancer treatment.

2. The method of claim 1, wherein the cancer is selected from adenocarcinoma, sarcoma, skin cancer, melanoma, bladder cancer, brain cancer, breast cancer, uterine cancer, ovarian cancer, prostate cancer, or lung cancer.

3. The method of claim 2, wherein said brain cancer is selected from an astrocytoma, meningioma, oligodendroglioma, mixed glioma and ependymoma.

4. The method of claim of 3, wherein the astrocytoma is a glioblastoma multiforme.

5. The method of claim 1, wherein said subject is a human.

6. (canceled)

7. The method of claim 1, wherein the radiation therapy is delivered by a radiation-delivering system, including a gantry-based system, a robotic radiosurgery system, a subcutaneous implant, or a radioisotope.

8. (canceled)

9. The method of claim 1 wherein said method further comprises:

- a. Obtaining or having obtained glioma cells from the subject;
- b. Testing or having tested the glioma cells in vitro for sensitivity to the DBD crystalline polymorph; and
- c. Administering the DBD crystalline polymorph to the subject who has demonstrated sensitivity in step (b).

10. A composition used to treat a patient with cancer comprising administering a therapeutically effective amount the DBD crystalline polymorph.

* * * * *